Arch Biopartners Inc.
ACHFF
$1.73
$0.010.58%
Weiss Ratings | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Weak | |||
Total Return Index | Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.58 | |||
Price History | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 0.00% | |||
30-Day Total Return | 55.56% | |||
60-Day Total Return | 56.25% | |||
90-Day Total Return | 57.66% | |||
Year to Date Total Return | 58.80% | |||
1-Year Total Return | 9.38% | |||
2-Year Total Return | -45.64% | |||
3-Year Total Return | 59.09% | |||
5-Year Total Return | 105.88% | |||
52-Week High % Change | -9.57% | |||
52-Week Low % Change | 136.11% | |||
Price | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $1.88 | |||
52-Week Low Price | $0.72 | |||
52-Week Low Price (Date) | Nov 02, 2023 | |||
52-Week High Price (Date) | Mar 18, 2024 | |||
Valuation | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 107.94M | |||
Enterprise Value | 111.52M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.02 | |||
Earnings Per Share Growth | -60.24% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 79.26 | |||
Price/Book (Q) | -24.96 | |||
Enterprise Value/Revenue (TTM) | 81.20 | |||
Price | $1.75 | |||
Enterprise Value/EBITDA (TTM) | -- | |||
Enterprise Value/EBIT | -103.57 | |||
Market Cap Category | Micro Cap | |||
Dividends and Shares | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 62.47M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 647-428-7031 | |||
Address | 27 Street Clair Avenue East Toronto, ON M4T 2M5 | |||
Website | www.archbiopartners.com | |||
Country | Canada | |||
Year Founded | -- | |||
Profitability | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -78.40% | |||
Profit Margin | -106.09% | |||
Management Effectiveness | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -131.43% | |||
Return on Equity | -- | |||
Income Statement | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 1.36M | |||
Total Revenue (TTM) | 1.36M | |||
Revenue Per Share | $0.02 | |||
Gross Profit (TTM) | 26.80K | |||
EBITDA (TTM) | -- | |||
EBIT (TTM) | -1.06M | |||
Net Income (TTM) | -1.44M | |||
Net Income Avl. to Common (TTM) | -1.44M | |||
Total Revenue Growth (Q YOY) | -31.60% | |||
Earnings Growth (Q YOY) | 63.79% | |||
EPS Diluted (TTM) | -0.02 | |||
EPS Diluted Growth (Q YOY) | 63.92% | |||
Balance Sheet | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 229.20K | |||
Cash Per Share (Q) | $0.00 | |||
Total Current Assets (Q) | 482.00K | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | -4.33M | |||
Current Ratio (Q) | 0.109 | |||
Book Value Per Share (Q) | -$0.07 | |||
Total Assets (Q) | 482.00K | |||
Total Current Liabilities (Q) | 4.43M | |||
Total Debt (Q) | 3.81M | |||
Total Liabilities (Q) | 4.81M | |||
Total Common Equity (Q) | -4.33M | |||
Cash Flow | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -1.00M | |||
Cash from Financing (TTM) | 1.43M | |||
Net Change in Cash (TTM) | 107.80K | |||
Levered Free Cash Flow (TTM) | 139.30K | |||
Cash from Operations (TTM) | -1.32M | |||